# EDGAR Filing Document

**Accession Number:** 0001159036
**File Stem:** 0001159036-26-000053
**Filing Date:** 2026-4
**Character Count:** 16458
**Document Hash:** 48ec9ad14ad87c3e7bc01c08414fe5da
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001159036-26-000053.hdr.sgml**: 20260430

**ACCESSION NUMBER**: 0001159036-26-000053

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 14

**CONFORMED PERIOD OF REPORT**: 20260430

**ITEM INFORMATION**: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20260430

**DATE AS OF CHANGE**: 20260430

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** HALOZYME THERAPEUTICS, INC.
- **CENTRAL INDEX KEY:** 0001159036
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 880488686
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-32335
- **FILM NUMBER:** 26920230

**BUSINESS ADDRESS:**
- **STREET 1:** 12390 EL CAMINO REAL
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92130
- **BUSINESS PHONE:** (858) 794-8889

**MAIL ADDRESS:**
- **STREET 1:** 12390 EL CAMINO REAL
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92130

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** HALOZYME THERAPEUTICS INC
- **DATE OF NAME CHANGE:** 20040312

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** GLOBAL YACHT SERVICES INC
- **DATE OF NAME CHANGE:** 20010912

?xml version='1.0' encoding='ASCII'? halo-20260430

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**____________________________________________**

**FORM 8-K** 

**_____________________________________________**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934**

---

| | |
|:---|:---|
| **Date of Report (Date of Earliest Event Reported):** | **April 30, 2026** |

---

![Halo Logo updated.jpg](halo-20260430_g1.jpg)

**HALOZYME THERAPEUTICS, INC.** 

**(Exact name of registrant as specified in its charter)**

**________________________**

**Commission File Number 001-32335** 

---

| | |
|:---|:---|
| **Delaware** | **88-0488686** |
| *(State or other jurisdiction of incorporation)* | *(I.R.S. Employer Identification No.)* |
| **12390 El Camino Real** | **92130** |
| **San Diego** | *(Zip Code)* |
| **California** | |
| *(Address of principal executive offices)* | |

---

**(858) 794-8889** 

*(Registrant's telephone number, including area code)*

**Not Applicable**

*(Former name or former address, if changed since last report)*

**________________________**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
| Common Stock, $0.001 par value | HALO | The Nasdaq Stock Market LLC |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

**Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

(c) On April 30, 2026, Halozyme Therapeutics, Inc. (the "Company") announced that Darren Snellgrove has been appointed to serve as the Company's Chief Financial Officer ("CFO"), effective June 8, 2026. Since May 2025, Mr. Snellgrove (age 52) has served as Vice President, Investor Relations at Johnson & Johnson, a multinational pharmaceutical, biotechnology and medical technologies corporation ("J&J"). From August 2021 to May 2025, he served as the CFO of J&J's Pharmaceutical sector. Previously he served in other finance leadership positions at J&J, including as CFO, VP Finance and Operations Pharmaceutical R&D from 2017 to August 2021, and as CFO, J&J Innovation from 2013 to 2017. Prior to 2013, Mr. Snellgrove served in other positions of increasing responsibility at J&J, including serving as CFO, Janssen Alzheimer Immunotherapy. Mr. Snellgrove holds a B.A. Honors Degree in Economics and Philosophy from Southampton University, England and an M.B.A. from Villanova University. Effective as of June 8, 2026, David Ramsay, the Company's current Interim CFO, will assume an advisory role with the Company to assist during a brief transition period.

In his role as CFO, Mr. Snellgrove will be paid an annual salary of $670,000 and he will be eligible to participate in the Company's executive officer incentive plans, with a bonus target equal to 50% of his base salary, which will be prorated in 2026. Beginning in 2027, Mr. Snellgrove will be eligible to receive long-term incentive awards in accordance with the Compensation Committee's equity award grant practices for the Company's executive officers. Mr. Snellgrove's 2027 long-term incentive award will have a minimum total grant date value of $4,000,000.

Upon joining the Company, Mr. Snellgrove will receive equity awards with a total grant date value of $7,200,000. This includes $3,200,000 in restricted stock units ("RSUs"), which is intended to make Mr. Snellgrove whole for equity value forfeited in connection with his acceptance of employment at Halozyme following 27 years of service at J&J, and vests one-third on each of the first three anniversaries of the date of grant. It also includes $4,000,000 in stock options that will vest 25% after one year and then in equal monthly installments over the next three years in accordance with the Company's standard equity award practices for the Company's executive officers. The equity award will be granted under, and be subject to the terms and conditions of, the Company's 2021 Stock Plan. As is customary and prevalent competitive practice when hiring an experienced executive of Mr. Snellgrove's caliber, the Compensation Committee provided the make-whole equity grant in RSUs ($3.2 million), while the balance of his new-hire equity awards was provided in stock options, which will deliver no value to Mr. Snellgrove absent an increase in our share price following his start date, in line with the Company's pay-for-performance philosophy.

Additionally, a sign-on cash bonus of $350,000 will be provided to Mr. Snellgrove upon joining the Company to make him whole for forgone cash compensation at his former employer. A prorated portion of the sign-on cash bonus is subject to repayment if, within 24 months of hire, Mr. Snellgrove voluntarily terminates his employment or is terminated for misconduct.

There are no family relationships between Mr. Snellgrove and any director, executive officer or person nominated or chosen by the Company to become a director or executive officer. Mr. Snellgrove does not have a direct or indirect material interest in any transaction or arrangement in which the Company is a participant.

On April 30, 2026, the Company issued a press release announcing the appointment of Mr. Snellgrove as CFO. A copy of the press release is attached hereto as Exhibit 99.1.

**Item 9.01 Financial Statements and Exhibits.**

Exhibits

---

| | |
|:---|:---|
| <u>Exhibit No.</u> | <u>Description</u> |
| <u>[99.1](darrensnellgrovepressrelea.htm)</u> | Press Release of Halozyme Therapeutics, Inc. dated April 30, 2026 |
| 104 | Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101) |

---

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | | |
|:---|:---|:---|:---|
| | | | Halozyme Therapeutics, Inc.<br>(Registrant) |
| Dated: | April 30, 2026 | By: | */s/ Mark Snyder* |
|  |  |  | Mark Snyder |
|  |  |  | Senior Vice President, General Counsel and Corporate Secretary |

---

## Exhibit 99.1

**Exhibit 99.1**![image_0.jpg](image_0.jpg)

**Halozyme Appoints Darren Snellgrove as Chief Financial Officer**

**SAN DIEGO, April 30, 2026** -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company") today announced the appointment of Darren Snellgrove as Chief Financial Officer (CFO), effective June 8, 2026.

Mr. Snellgrove will be responsible for leading Halozyme's financial operations and strategy, including capital allocation, corporate development and investor relations. Darren will report to Helen Torley, President and Chief Executive Officer.

"I am delighted to have a financial leader of Darren's experience and caliber join Halozyme at this exciting time. He is a highly respected finance leader with deep experience and an expansive skillset, demonstrated by successful leadership across major portfolio investments and a strong, well-established record of investor engagement," said Dr. Helen Torley, President and Chief Executive Officer of Halozyme. "I look forward to having Darren join our leadership team and contribute to the acceleration of value creation for our shareholders."

Mr. Snellgrove brings more than 30 years of exceptional financial leadership, strategic insight, and operational excellence across the biopharmaceutical and medtech sectors. Most recently, he led investor relations at Johnson & Johnson, a Fortune 50 healthcare company. In that role, he reshaped corporate messaging and investor engagement strategies, strengthened analyst and shareholder relationships, and supported strong market performance.

Previously, Mr. Snellgrove served as Chief Financial Officer of Johnson & Johnson's Pharmaceuticals sector, where he provided global financial leadership for a business generating more than $50 billion in annual revenue. During his tenure, he delivered impressive financial results, leading large global teams across commercial operations, R&D, supply chain, and business development, and played a central role in major portfolio investments, restructuring initiatives, and business development transactions.

Earlier in his career, Mr. Snellgrove held CFO and senior finance leadership roles across pharmaceutical R&D, innovation, and M&A at Johnson & Johnson, as well as progressive finance roles at Centocor prior to its acquisition.

"I am thrilled to join Halozyme at such an important time in the Company's evolution," said Mr. Snellgrove. "Halozyme's technology has dramatically improved the delivery of biologics for patients, and the company has built a broad technology portfolio with strong partners, durable

------

royalty streams, and significant long-term opportunity. I look forward to working with Helen and the entire team to drive sustainable growth and value creation for shareholders."

Mr. Snellgrove holds an MBA from Villanova University and a BA Honors degree from the University of Southampton in England.

**About Halozyme**

Halozyme is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. As the innovators of ENHANZE<sup>®</sup> drug delivery technology with the proprietary enzyme rHuPH20, Halozyme's commercially-validated solution facilitates the subcutaneous delivery of injected drugs and fluids, reducing treatment burden and improving convenience. ENHANZE<sup>®</sup> has touched more than one million patient lives through ten commercialized products across over 100 global markets and is licensed to leading pharmaceutical and biotechnology companies including Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly, Bristol-Myers Squibb, argenx, ViiV Healthcare, Chugai Pharmaceutical, Acumen Pharmaceuticals, Merus N.V. and Skye Bioscience.

Halozyme expanded its drug delivery technology portfolio to develop partner products using Hypercon™ and Surf Bio's hyperconcentration technology. Hypercon™ is an innovative microparticle technology expected to set a new standard in hyperconcentration of drugs and biologics by reducing injection volume for the same dosage and enabling administration in at-home and healthcare-provider settings. The addition of Surf Bio's polymer-based hyperconcentration technology further broadens the range of biologics that can be delivered subcutaneously, meaningfully expanding the scope of opportunities across therapeutic modalities. Together, Hypercon™ and Surf Bio's technology complement ENHANZE<sup>®</sup> by enabling creation and delivery of highly concentrated biologics. The Hypercon™ technology has been licensed to leading biopharmaceutical partners, including Janssen, Eli Lilly, argenx and Vertex Pharmaceuticals.

Halozyme also develops, manufactures and commercializes drug-device combination products using advanced auto-injector technologies designed to improve convenience, reliability and tolerability, enhancing patient comfort and adherence. The Company has two proprietary commercial products, Hylenex<sup>®</sup> and XYOSTED<sup>®</sup>, partnered commercial products and ongoing development programs with Teva Pharmaceuticals and McDermott Laboratories Limited, an affiliate of Viatris Inc.

Halozyme is headquartered in San Diego, CA, with offices in Ewing, NJ; Minnetonka, MN; and Boston, MA. Minnetonka is also the site of its operations facility.

For more information, visit www.halozyme.com and connect with us on LinkedIn.

------

**Forward-Looking Statements**

This press release may include forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts and may include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential and statements regarding Halozyme's future performance, durability of revenues, shareholder value creation and growth of Halozyme's business. Forward-looking statements are generally identified by the words "expects", "anticipates", "believes", "intends", "estimates", "plans", "will be" and similar expressions. Although Halozyme believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Halozyme, that could cause actual results and developments to differ materially from those expressed in the forward-looking information and statements. Actual results could differ materially from the expectations contained in these forward-looking statements as a result of several factors, including unexpected levels of revenues, expenditures, costs and growth. These and other factors that may result in differences are discussed in greater detail in the Company's most recently filed Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission, including under the headings "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations". Halozyme undertakes no obligation to update or revise any forward-looking statements or any other information contained herein.

**Contacts:** 

Tram Bui

VP, Investor Relations and Corporate Communications

609-333-7668

<u>tbui@halozyme.com</u>

Sydney Charlton

Teneo

917-972-8407

<u>sydney.charlton@teneo.com</u>

<br>